Accessibility StatementSkip Navigation CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rhCollagen), today announced positive results from its non-clinical program eva ...

CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc’s drug discovery engine and helps accelerate its mission to develop therapies for c ...

Core Insights - NeOnc Technologies Holdings, Inc. reported financial results for Q2 2025, highlighting significant operational achievements and upcoming milestones in their clinical pipeline [1][4]. Clinical Pipeline Progress - NEO100-01, an intranasal therapy for malignant gliomas, and NEO212, a bio-conjugated therapy for brain cancer, are advancing with the final patient cohort in Phase I expected to complete dosing in 2025 [3]. - A pediatric indication trial, NEO100-3, has been initiated with patient recruitment currently underway [3]. Financial Results for Q2 2025 - General and administrative (G&A) expenses increased to $984K from $290K in Q2 2024, attributed to expanded marketing, rent, travel, and costs related to the Middle East partnership [7]. - Research and development (R&D) expenses rose to $677K from $394K in Q2 2024, driven by additional trial sites and increased recruitment efforts [7]. - The net loss for the quarter was $5.68 million, or $0.30 per diluted share, compared to a net loss of $4.52 million, or $0.27 per diluted share in Q2 2024 [7]. Strategic Developments - A $50 million strategic partnership with Quazar Investment has been secured, which will enhance NeOnc's clinical trials platform in the GCC & MENA regions [6]. - The company received $2.5 million in STTR grants from NIH to support the advancement of NEO212 for gliomas and leukemia [6]. - NeOnc has signed an agreement to acquire an AI, 3D bioprinting, and quantum modeling intellectual property portfolio [6]. - The company has been included in the Russell Microcap Index, increasing visibility among institutional investors [6]. Upcoming Catalysts - Full enrollment for the NEO100-01 Phase 2a trial is expected by September 2025, with top-line data readout anticipated in early 2026 [10]. - Completion of the NEO212 Phase I final cohort dosing is also expected in 2025 [10].

CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Paten ...

Core Viewpoint - CollPlant Biotechnologies has appointed Bowman Bagley as Vice President, Commercial North America, to enhance its growth strategy and market presence for rhCollagen products [1][2]. Company Overview - CollPlant is focused on regenerative and aesthetic medicine, utilizing non-animal-derived recombinant human collagen (rhCollagen) for its products [5]. - The company aims to innovate in areas such as 3D bioprinting, tissue repair, and medical aesthetics [5]. Leadership Appointment - Bowman Bagley will oversee the commercial strategy, including sales, marketing, and logistics for CollPlant's rhCollagen-based products in North America [1][2]. - Bagley has extensive experience in collagen-based biomaterials and has held leadership roles in sales and product development [2][3]. Strategic Goals - The appointment of Bagley is expected to accelerate the growth of CollPlant's bioinks portfolio and expand rhCollagen sales in both research markets and strategic collaborations [2]. - The company has previously entered into a significant agreement with Allergan for dermal and soft tissue fillers, indicating a strong market position [6].

Core Viewpoint - Organovo Holdings, Inc. will rebrand as VivoSim Labs, Inc. and will begin trading under the new ticker symbol "VIVS" on April 24, 2025 [1]. Group 1 - The name change to VivoSim Labs, Inc. will be effective on April 24, 2025 [1]. - The company's common stock will continue to be listed on the Nasdaq Capital Market [2]. - Existing stockholders do not need to take any action regarding the name and ticker symbol change [2].